Jason K Cullen, Pei-Yi Yap, Blake Ferguson, Zara C Bruce, Motoko Koyama, Herlina Handoko, Kevin Hendrawan, Jacinta L Simmons, Kelly M Brooks, Jenny Johns, Emily S Wilson, Marjorie M A de Souza, Natasa Broit, Praphaporn Stewart, Daniel Shelley, Tracey McMahon, Steven M Ogbourne, Tam Hong Nguyen, Yi Chieh Lim, Alberto Pagani, Giovanni Appendino, Victoria A Gordon, Paul W Reddell, Glen M Boyle, Peter G Parsons
BACKGROUND: Tigilanol tiglate (TT) is a protein kinase C (PKC)/C1 domain activator currently being developed as an intralesional agent for the treatment of various (sub)cutaneous malignancies. Previous work has shown that intratumoral (I.T.) injection of TT causes vascular disruption with concomitant tumor ablation in several preclinical models of cancer, in addition to various (sub)cutaneous tumors presenting in the veterinary clinic. TT has completed Phase I dose escalation trials, with some patients showing signs of abscopal effects...
April 24, 2024: Journal for Immunotherapy of Cancer